These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 3008292)

  • 41. Diseases caused by antibodies to receptors.
    Flier J
    Clin Immunol Rev; 1981-1982; 1(2):215-56. PubMed ID: 6299639
    [No Abstract]   [Full Text] [Related]  

  • 42. Production and assay of antibodies to acetylcholine receptors.
    Lindstrom J; Einarson B; Tzartos S
    Methods Enzymol; 1981; 74 Pt C():432-60. PubMed ID: 7321891
    [No Abstract]   [Full Text] [Related]  

  • 43. Immunisation with Torpedo acetylcholine receptor.
    Elfman L
    Prog Neurobiol; 1984; 23(1-2):39-62. PubMed ID: 6097937
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Enzyme-linked immunosorbent assay for antibody against the nicotinic acetylcholine receptor in human myasthenia gravis.
    Kawanami S; Tsuji R; Oda K
    Ann Neurol; 1984 Feb; 15(2):195-200. PubMed ID: 6367620
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Content of acetylcholine receptor and antibodies bound to receptor in myasthenia gravis, experimental autoimmune myasthenia gravis, and Eaton-Lambert syndrome.
    Lindstrom JM; Lambert EH
    Neurology; 1978 Feb; 28(2):130-8. PubMed ID: 202890
    [No Abstract]   [Full Text] [Related]  

  • 46. Respective role of thymus and muscle in autoimmune myasthenia gravis.
    Moulian N; Wakkach A; Guyon T; Poëa S; Aïssaoui A; Levasseur P; Cohen-Kaminsky S; Berrih-Aknin S
    Ann N Y Acad Sci; 1998 May; 841():397-406. PubMed ID: 9668265
    [No Abstract]   [Full Text] [Related]  

  • 47. [Immunological findings in patients with myasthenia gravis (MG)].
    Oosterhuis HJ
    Ned Tijdschr Geneeskd; 1976 May; 120(20):882-4. PubMed ID: 1083960
    [No Abstract]   [Full Text] [Related]  

  • 48. Thymic myogenesis, T-lymphocytes and the pathogenesis of myasthenia gravis.
    Wekerle H; Hohlfeld R; Ketelsen UP; Kalden JR; Kalies I
    Ann N Y Acad Sci; 1981; 377():455-76. PubMed ID: 6978664
    [No Abstract]   [Full Text] [Related]  

  • 49. How subtle differences in MHC class II affect the severity of experimental myasthenia gravis.
    Yang B; McIntosh KR; Drachman DB
    Clin Immunol Immunopathol; 1998 Jan; 86(1):45-58. PubMed ID: 9434796
    [TBL] [Abstract][Full Text] [Related]  

  • 50. T cell responses in EAMG-susceptible and non-susceptible mouse strains after immunization with overlapping peptides encompassing the extracellular part of Torpedo californica acetylcholine receptor alpha chain. Implication to role in myasthenia gravis of autoimmune T-cell responses against receptor degradation products.
    Oshima M; Yokoi T; Deitiker P; Atassi MZ
    Autoimmunity; 1998; 27(2):79-90. PubMed ID: 9583739
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Autoimmunity to acetylcholine receptors in myasthenia gravis.
    Vincent A
    Biochem Soc Trans; 1991 Feb; 19(1):180-3. PubMed ID: 2037143
    [No Abstract]   [Full Text] [Related]  

  • 52. Prevention and therapy with electrolectin of experimental autoimmune myasthenia gravis in rabbits.
    Levi G; Tarrab-Hazdai R; Teichberg VI
    Eur J Immunol; 1983 Jun; 13(6):500-7. PubMed ID: 6861875
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cytophilic antibodies in experimental autoimmune myasthenia gravis.
    Martinez RD; Tarrab-Hazdai R; Aharonov A; Fuchs S
    J Immunol; 1977 Jan; 118(1):17-20. PubMed ID: 830746
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Immunological similarities between an experimental autoimmune myasthenia gravis model and human myasthenia gravis.
    Souan ML; Geffard M
    Neurosci Lett; 1986 Aug; 68(3):282-7. PubMed ID: 2427976
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Autoimmune aspects of myasthenia gravis.
    Lisak RP; Levinson AI; Zweiman B
    Concepts Immunopathol; 1985; 2():65-101. PubMed ID: 3916415
    [No Abstract]   [Full Text] [Related]  

  • 56. [alpha-Bungarotoxin and acetylcholine receptor (author's transl)].
    Takamori M; Ishii N; Tsujihata M; Mori M; Kasai M
    No To Shinkei; 1977 Jun; 29(6):597-607. PubMed ID: 334200
    [No Abstract]   [Full Text] [Related]  

  • 57. The effects of T cell subpopulations and recombinant interleukin (IL)-2 on peripheral B cell function in patients with myasthenia gravis.
    Zhang J; Zhou WB; Wang HL; Guo SS
    Hum Antibodies; 1997; 8(2):90-4. PubMed ID: 9289393
    [TBL] [Abstract][Full Text] [Related]  

  • 58. B-T lymphocyte interactions in experimental autoimmune myasthenia gravis: autoantibody mediated up-regulation of the response of acetylcholine receptor-specific T lymphocytes.
    Zhang Y; Tzartos S
    Immunology; 1992 Dec; 77(4):571-6. PubMed ID: 1283599
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Deficient T-cell mitogen response in murine experimental autoimmune myasthenia gravis: a defect in the adherent cell population.
    Christadoss P; Dauphinee M; Lindstrom J; Dang H; Fernandes G; Talal N
    Cell Immunol; 1983 Jul; 79(2):358-66. PubMed ID: 6223709
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Myasthenia gravis. Prototype of an anti-receptor autoaggression disease (author's transl)].
    Hohlfeld R; Wekerle H
    MMW Munch Med Wochenschr; 1981 Jul; 123(31):1207-11. PubMed ID: 6790965
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.